Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amgen scoops up Dezima for $300mm plus potential earn-outs of $1.25bn

Executive Summary

Concurrent with signing a potential $1.75bn monoclonal antibody development deal with Xencor, Amgen Inc. is acquiring cardiovascular-focused start-up Dezima Pharma BV for $300mm in cash up front, up to $1.25bn in earn-outs based on development and sales achievements, and low single-digit royalties.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash for Equity

Related Companies